1-7 of 7
Floralyn Mendoza, BS
Close
Sort by
Journal Articles

Pre Transplant Values of C Reactive Protein (CRP) and Brain Natriuretic Peptide (BNP) as Predictors of Transplant Outcomes in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndromes (AML/MDS) Undergoing Allogeneic Stem Cell Transplantation (AlloSCT).

Sergio Giralt, MD, Rima M. Saliba, PhD, Floralyn Mendoza, BS, Gaurav Parikh, MD, Suheil Qureshi, MD, Weiqing Zhang, MD, Uday Popat, MD, Muzaffar Qazilbash, MD, Issa Khouri, MD, Chitra Hosing, MD, Amin Alousi, MD, Paolo Anderlini, MD, Borje Andersson, MD, PhD, Roy Jones, MD, PhD, Elizabeth Shpall, MD, Partow Kebriaei, MD, Yago Nieto, MD, PhD, Naoto Ueno, MD, PhD, Richard Champlin, MD, Marcos de Lima, MD
Journal: Blood
Blood (2007) 110 (11): 1984.
https://doi.org/10.1182/blood.V110.11.1984.1984
Published: 2007
Journal Articles

Autotransplantation in Patients with Multiple Myeloma and Concurrent Renal Failure Is Safe and Feasible and Associated with Recovery of Renal Function in > 30% of Patients.

Gaurav C. Parikh, MD, MPH (2nd Year), Rima M. Saliba, Ph.D., Amit Lahoti, MD, Chitra Hosing, MD, Floralyn Mendoza, BS, Suhail R. Qureshi, MD, Donna M. Weber, MD, BS, Michael Wang, MD, MS, Uday Popat, MD, Amin Alousi, MD, Richard E. Champlin, MD, Sergio A. Giralt, MD, Muzaffar H. Qazilbash, MD
Journal: Blood
Blood (2007) 110 (11): 5126.
https://doi.org/10.1182/blood.V110.11.5126.5126
Published: 2007
Journal Articles

A Non-Myeloablative Regimen of Fludarabine and Melphalan Is Safe and Well Tolerated for Allogeneic Transplantation in Multiple Myeloma.

Muzaffar H. Qazilbash, MD, Rima M. Saliba, PhD, Gaurav C. Parikh, MD, Chitra Hosing, MD, Floralyn Mendoza, BS, Donna M. Weber, MD, Michael Wang, MD, Sheeba K. Thomas, MD, Thuy S. Flosser, BS, Partow Kebriaei, MD, Uday Popat, MD, Amin M. Alousi, MD, Marcos de Lima, MD, Richard E. Champlin, MD, Sergio A. Giralt
Journal: Blood
Blood (2007) 110 (11): 3032.
https://doi.org/10.1182/blood.V110.11.3032.3032
Published: 2007
Journal Articles

Retrospective Comparison of Transplant Outcomes in Patients with Multiple Myeloma According to Induction Therapy with Thalidomide/Dexamethasone (TD) with or without Bortezomib (VTD).

Sergio Giralt, MD, Rupi Thandi, MD, Muzaffar Qazilbash, MD, Floralyn Mendoza, BS, Eric Han, BS, Chitra Hosing, MD, Michael Wang, MD, Sheeba Thomas, MD, Raymond Alexanian, MD, Richard Champlin, MD, Donna Weber, MD
Journal: Blood
Blood (2007) 110 (11): 948.
https://doi.org/10.1182/blood.V110.11.948.948
Published: 2007
Journal Articles

Transplant Outcomes after Topotecan-Melphalan-Cyclophosphamide (TMC) Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma. Comparison to Melphalan 200 mg/M2 (MEL200).

Michele Donato, MD, Ana Aleman, MD, Donna Weber, MD, Michael Wang, MD, Muzaffer Qazilbasch, MD, Marilyn Davis, R.N., Linda Roden, MD, Floralyn Mendoza, BS, Richard Champlin, MD, Sergio Giralt, MD
Journal: Blood
Blood (2005) 106 (11): 1177.
https://doi.org/10.1182/blood.V106.11.1177.1177
Published: 2005
Journal Articles

Risk Factors for Development of Symptoms Post Autologous Transplant for Multiple Myeloma.

Erica Campagnaro, MD, Rima Saliba, Ph.D, Karen Anderson, Ph.D, Linda Roden, MD, Floralyn Mendoza, BS, Ana Aleman, MD, Charles Cleeland, Ph.D, Donna Weber, MD, Jane Brown, RN, Sergio Giralt, MD
Journal: Blood
Blood (2005) 106 (11): 1771.
https://doi.org/10.1182/blood.V106.11.1771.1771
Published: 2005
Journal Articles

Impact of Holmium-DOTMP on Transplant Outcomes. Results of a Retrospective Single Institution Analysis.

Anna Christoforidou, MD, Patricia Williams, RN, Linda Roden, MD, Ana Aleman, MD, Donna Weber, MD, Floralyn Mendoza, BS, Donald Podoloff, MD, Hazel Breitz, MD, Raymond Alexanian, MD, Richard Champlin, MD, Sergio Giralt, MD
Journal: Blood
Blood (2005) 106 (11): 426.
https://doi.org/10.1182/blood.V106.11.426.426
Published: 2005